Premium
COVID‐19 associated pulmonary aspergillosis
Author(s) -
Koehler Philipp,
Cornely Oliver A.,
Böttiger Bernd W.,
Dusse Fabian,
Eichenauer Dennis A.,
Fuchs Frieder,
Hallek Michael,
Jung Norma,
Klein Florian,
Persigehl Thorsten,
Rybniker Jan,
Kochanek Matthias,
Böll Boris,
ShimabukuroVornhagen Alexander
Publication year - 2020
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.13096
Subject(s) - ards , medicine , aspergillosis , pulmonary aspergillosis , intensive care medicine , intensive care unit , covid-19 , retrospective cohort study , lung , disease , infectious disease (medical specialty) , immunology
Summary Objectives Patients with acute respiratory distress syndrome (ARDS) due to viral infection are at risk for secondary complications like invasive aspergillosis. Our study evaluates coronavirus disease 19 (COVID‐19) associated invasive aspergillosis at a single centre in Cologne, Germany. Methods A retrospective chart review of all patients with COVID‐19 associated ARDS admitted to the medical or surgical intensive care unit at the University Hospital of Cologne, Cologne, Germany. Results COVID‐19 associated invasive pulmonary aspergillosis was found in five of 19 consecutive critically ill patients with moderate to severe ARDS. Conclusion Clinicians caring for patients with ARDS due to COVID‐19 should consider invasive pulmonary aspergillosis and subject respiratory samples to comprehensive analysis to detect co‐infection.